Monique Minnema
@moniqueminnema.bsky.social
Professor of hematology, specialisation B cell malignancies, head of clinical trial team & ERN UMC Utrecht #UMCUtrecht #hematology
Reposted by Monique Minnema
Extremely proud of my team & collaborators for this beautiful work, now freely available @natcomms.nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation - Nature Communications
Chimeric antigen receptor (CAR) T cells specific for an antigen, BCMA, have shown efficacy in controlling multiple myeloma in some patients, but responses vary. Here the authors show that, by over-exp...
www.nature.com
May 19, 2025 at 1:36 PM
Extremely proud of my team & collaborators for this beautiful work, now freely available @natcomms.nature.com
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Monique Minnema
The Clinical Trials Information System #CTIS has been designated as primary registry by the @who.int !
This designation represents a significant step forward in promoting transparency and trust in clinical research in the EU.
#clinicaltrials #clinicalresearch www.ema.europa.eu/en/news/clin...
This designation represents a significant step forward in promoting transparency and trust in clinical research in the EU.
#clinicaltrials #clinicalresearch www.ema.europa.eu/en/news/clin...
Clinical Trials Information System designated as WHO primary registry | European Medicines Agency (EMA)
Designation facilitates data sharing, promotes transparency and trust in clinical research
www.ema.europa.eu
April 3, 2025 at 8:03 AM
The Clinical Trials Information System #CTIS has been designated as primary registry by the @who.int !
This designation represents a significant step forward in promoting transparency and trust in clinical research in the EU.
#clinicaltrials #clinicalresearch www.ema.europa.eu/en/news/clin...
This designation represents a significant step forward in promoting transparency and trust in clinical research in the EU.
#clinicaltrials #clinicalresearch www.ema.europa.eu/en/news/clin...
Our paper on use of zanubrutinib in patients with Bing Neel Syndrome is out: eur05.safelinks.protection.outlook.com?url=https%3A...
In this retrospective analysis of 30 patients, the clinical response rate was high (92%), which also happens in the majority of patients in the first 3 months.
In this retrospective analysis of 30 patients, the clinical response rate was high (92%), which also happens in the majority of patients in the first 3 months.
Zanubrutinib in Bing Neel syndrome: efficacy and tolerability - Leukemia
Leukemia - Zanubrutinib in Bing Neel syndrome: efficacy and tolerability
eur05.safelinks.protection.outlook.com
March 31, 2025 at 11:39 AM
Our paper on use of zanubrutinib in patients with Bing Neel Syndrome is out: eur05.safelinks.protection.outlook.com?url=https%3A...
In this retrospective analysis of 30 patients, the clinical response rate was high (92%), which also happens in the majority of patients in the first 3 months.
In this retrospective analysis of 30 patients, the clinical response rate was high (92%), which also happens in the majority of patients in the first 3 months.